LONRF2

Across TCGA pan-cancer cohorts, LONRF2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LONRF2 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LONRF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LONRF2 expression acts as an unfavorable survival marker.

UCEC are the cancer types where LONRF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	II,III,IV	0.450	0.908	.041	8	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

LONRF2–UCEC (DFS)

Open the UCEC breakdown →